JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations

The adaptive use of Janus kinase (JAK)-inhibitors has been suggested by rheumatology experts in the management of COVID-19. We recount the rationale behind their use in this setting, and the current evidence for and against their use in this review. JAK-inhibitors role in COVID-19 infection appears...

Descripción completa

Detalles Bibliográficos
Autores principales: Menshawey, Rahma, Menshawey, Esraa, Alserr, Ayman H.K., Abdelmassih, Antoine Fakhry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103822/
https://www.ncbi.nlm.nih.gov/pubmed/34109302
http://dx.doi.org/10.1097/XCE.0000000000000237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103822/
https://www.ncbi.nlm.nih.gov/pubmed/34109302
http://dx.doi.org/10.1097/XCE.0000000000000237

Ejemplares similares